bt8009
Peptideexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jul 17, 2020 (NCT04561362)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 2/Phase 3
- Esophageal Neoplasms · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
- Nectin-4BINDING AGENT
NECTIN4 binding agent
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06933329 | Phase 2 | Jul 18, 2025 | Bicycle Therapeutics |
| NCT06840483 | Phase 2 | Mar 3, 2025 | Bicycle Therapeutics |
| NCT06225596 | Phase 2/Phase 3 (Phase 3) | Jan 24, 2024 | Bicycle Therapeutics |
| NCT04561362 | Phase 1/Phase 2 (Phase 2) | Jul 17, 2020 | Bicycle Therapeutics, Tennessee Oncology, PLLC |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bicycle Therapeutics | For profit | 4 | 4 | 2 | 2020 |
| Tennessee Oncology, PLLC | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1